ASCP MLT Study Guide: Laboratory Reasoning

1. Pretransfusion specimen checks

In pretransfusion testing, the identity on the tube must connect the blood to the patient at collection. An order number or matching paperwork cannot prove whose blood entered an unlabeled tube. Compare the required patient identifiers on the specimen and request, collection details, specimen age under the applicable testing rules, and any history that changes the testing window. Inspect for clots, hemolysis, inadequate volume, or an unsuitable anticoagulant before choosing a test. EDTA plasma is commonly used because it limits complement activation after collection, but the validated method determines acceptable specimens. A mismatch or missing identifier calls for a new, correctly identified collection, not an inferred correction. In the U.S. ASCP MLT setting, this check protects every later typing and crossmatch result: even flawless analytical work cannot make an unidentified specimen safe.

Worked example: A pretransfusion EDTA tube carries the correct order number but no patient identifier. The request lists two identifiers, and the collection paperwork appears complete. Those records link the order to a patient, but none establishes whose blood is in this tube. Hold compatibility testing, record the discrepancy, and follow the rejection and recollection process. Do not add a patient label after receipt.

Watch the distinction: A matching order number does not substitute for patient identification on the tube. It identifies a request, while compatibility testing requires confidence in the blood's source.

2. ABO typing and discrepancies

Forward ABO typing tests antigens on patient red cells with anti-A and anti-B. Reverse typing tests patient plasma against known A and B cells for the expected antibodies. In a typical group A result, cells carry A antigen and plasma reacts with B cells through anti-B. Read the two sides together rather than choosing whichever looks stronger. Weak reverse reactions may reflect low antibody concentration, while unexpected forward reactions can arise from mixed cell populations, weak antigen expression, or technical error. Check identification, reagent controls, reaction strength, and recent transfusion history; repeat or extend testing with an appropriate method when results conflict. A discrepancy remains unresolved until the observed reactions and the assigned group agree. For MLT(ASCP) practice questions, write the expected forward and reverse pattern first, then compare each actual reaction with it.

Worked example: Patient cells react with anti-A but not anti-B. Patient plasma reacts with reagent B cells but not A cells. Forward typing shows A antigen; reverse typing shows the expected anti-B, so both support group A. If the B-cell reaction were absent, the reverse type would be incomplete. Verify controls and investigate weak or missing plasma antibody before assigning a group.

Watch the distinction: A clear forward type does not erase a conflicting reverse type. The discordance may reveal a specimen problem or a biologically important typing complication.

3. Rh and other red-cell antigens

Red-cell antigens are inherited structures on the cell membrane. Rh D is highly relevant because exposure to D-positive red cells can stimulate anti-D in a D-negative person. Anti-D is usually an IgG antibody that reacts at body temperature, so it can matter in transfusion and cross the placenta during pregnancy. Other systems, including Kell, Kidd, and Duffy, also contain antigens whose antibodies may cause hemolysis. Antigen presence on a donor unit and antibody presence in the recipient must therefore be considered together. A negative antibody screen does not prove that every historical antibody has disappeared permanently; previously formed antibodies may fall below detection and rise again after exposure. Check documented antibody history and select the required antigen-negative units for compatibility testing. The laboratory identifies and reports the serologic risk; clinical decisions about treatment belong to the care team.

Worked example: A D-negative patient has documented anti-D. One proposed red-cell unit types D-positive and another D-negative. The D-positive unit presents the antigen targeted by the patient's antibody, so it does not meet the stated selection requirement. Choose the D-negative unit, confirm its identity and type, and perform the required compatibility testing before routine release.

Watch the distinction: Do not treat an undetectable antibody today as proof of no risk. A documented past antibody can remain relevant when selecting donor red cells.

4. Antiglobulin testing

Antiglobulin reagent detects human immunoglobulin or complement attached to red cells, making otherwise invisible sensitization observable as agglutination. A direct antiglobulin test examines the patient's red cells for coating that occurred in the body. An indirect test first incubates patient plasma with test red cells, then detects antibody bound during laboratory testing; it supports antibody screening and compatibility work. Washing before adding antiglobulin reagent removes unbound immunoglobulin. Incomplete washing can leave free antibody that neutralizes the reagent and causes a false negative. After a negative antiglobulin reaction, IgG-coated check cells should agglutinate if the reagent was added and remains active. A failed check-cell reaction invalidates that negative result and requires investigation. A positive direct test establishes coating, but further evidence is needed to identify the coating agent and its clinical significance.

Worked example: A patient's direct antiglobulin test is positive, indicating red-cell coating in vivo. Their indirect test appears negative, but the IgG-coated check cells also fail to react. The indirect result is invalid: omitted or inactive antiglobulin reagent, or neutralization by residual free antibody, remains possible. Repeat with valid washing, reagent, and controls before interpreting the indirect test.

Watch the distinction: A positive direct antiglobulin test does not by itself prove hemolysis. It shows cell coating; hemolysis assessment and clinical context determine what that finding means.

5. Antibody panel reasoning

Start an antibody panel by marking which reagent cells react, at what phase and strength, and which antigens each cell carries. An antibody candidate should account for positive cells while generally being absent from nonreactive cells. The autocontrol compares patient plasma with the patient's own cells and can suggest an autoantibody when positive, though it is not a complete explanation by itself. Some antibodies show dosage: cells expressing an antigen from both inherited copies may react more strongly than cells expressing one copy. Weak reactions can therefore complicate exclusions. Recent transfusion can also make the patient's red-cell phenotype unreliable for determining inherited antigen status. Check reaction conditions, selected cells, required exclusions, and antibody history before naming specificity. Several antibodies can coexist, and a small panel may lack the antigen combinations needed to separate them.

Worked example: At the antiglobulin phase, two K-positive panel cells react and three K-negative cells do not. The autocontrol is negative. Anti-K fits this pattern, but five cells may also share other antigens in a misleading way. Test suitable selected cells and complete the required exclusions. Report anti-K only when the full evidence supports it; retain any unresolved possibilities for further work.

Watch the distinction: Two reacting K-positive cells do not prove anti-K if other antigens track with K on those cells. Use discriminating cells before settling on specificity.

6. Compatibility decisions

Compatibility work begins with patient identification, ABO and Rh typing, antibody screening, and review of any previous clinically significant antibody. When such an antibody is known, select donor red cells lacking the corresponding antigen and use the required crossmatch method to assess compatibility. An immediate-spin or electronic approach may be appropriate only under the laboratory's defined eligibility conditions; neither replaces testing needed for a relevant antibody. A compatible crossmatch also does not repair incorrect patient identification or an unrecognized antibody. If blood is needed before routine work is complete, emergency release follows a separate authorization and documentation pathway, with remaining testing completed and discrepancies communicated promptly. Keep unit selection, testing status, and release status distinct in the record. Medical laboratory technician certification study is most useful here when each decision follows the antibody and unit data supplied.

Worked example: A patient has established anti-K. Unit A is K-positive; unit B is confirmed K-negative. Select unit B and perform the required crossmatch, because its lack of K addresses the known antibody while testing checks compatibility under the stated method. If the care team requests release before testing finishes, use the distinct emergency authorization and record the incomplete work.

Watch the distinction: An antigen-negative label alone does not mean a unit has completed compatibility testing. Verify the unit's identity and antigen result, then perform the required crossmatch.

7. Donors and blood components

Donor suitability depends on the specific rules supplied for the collection, including history, collection interval, and any required testing. Apply those criteria to the facts given; a historical convention should not be treated as a universal current rule. Autologous collection is intended for the donor's own use, while allogeneic components may be supplied to another patient, and their processing paths differ. Component choice follows what the order requests: red cells provide oxygen-carrying cells, platelets support primary hemostasis, plasma supplies soluble coagulation factors, and cryoprecipitate concentrates selected plasma proteins. Modified components meet particular stated requirements, such as irradiation or leukocyte reduction. Before issue, verify component identity, compatibility requirements, expiration, storage and transport conditions, and relevant processing or quality records. A correctly chosen component can still be unsuitable if its identity or handling history is uncertain.

Worked example: A hypothetical donor rule requires at least 60 days since the previous collection. The donor reports 45 days, leaving 60 − 45 = 15 days before meeting that stated interval, so defer under this rule. In a separate platelet request, verify that the selected unit is a platelet component and that its identification, handling, expiration, and quality records meet the supplied requirements.

Watch the distinction: Do not apply a hypothetical collection interval as a current rule for every donor. Use the criteria stated for the case and check component suitability separately.

8. Transfusion reaction investigation

A suspected transfusion reaction requires prompt communication so the clinical team can stop or manage the transfusion while the laboratory investigates. Begin with patient and unit identity, labels, issue records, and a check for clerical mismatch. Compare pretransfusion and posttransfusion specimens for visible hemolysis, and repeat relevant ABO testing or a direct antiglobulin test as indicated by the reaction workup. A newly positive DAT or evidence of hemolysis strengthens concern for an immune hemolytic process, but neither single result identifies the full cause. Fever can also accompany a nonhemolytic reaction or another patient condition. Assess specimen quality and timing because traumatic collection can make posttransfusion plasma appear hemolyzed. Document findings, preserve required materials, and escalate urgent discrepancies. The technician reports the observed laboratory pattern and promptly alerts the authorized team without assigning a definitive diagnosis.

Worked example: Soon after transfusion starts, a patient develops fever and posttransfusion plasma looks dark. Notify the authorized team immediately. Recheck patient and unit identifiers, compare the earlier and later plasma, and perform the specified DAT and repeat typing or follow-up tests. Dark plasma raises concern for hemolysis, while fever alone does not establish its mechanism. Record and escalate the findings.

Watch the distinction: Fever during transfusion is not automatically a febrile nonhemolytic reaction. Investigate identification errors and possible hemolysis before narrowing the cause.

9. Maternal and newborn testing

Maternal IgG against a fetal red-cell antigen can cross the placenta and coat fetal cells. Evaluate the maternal antibody history and specificity alongside newborn antigen typing, the direct antiglobulin test, hemoglobin, bilirubin, and their trends. A positive newborn DAT supports red-cell coating but does not measure the degree of hemolysis by itself. Conversely, a falling hemoglobin or rising bilirubin needs timely review even if one serologic finding is weak. Fetomaternal-hemorrhage estimates use a measured fetal-cell fraction and an assumed maternal blood volume; the estimate depends on sample quality and the method's limitations. Multiplying the fraction by maternal blood volume estimates fetal whole-blood volume under those assumptions. It is a laboratory estimate for further assessment, not a treatment instruction. Communicate concerning findings promptly through the authorized pathway.

Worked example: A mother has anti-D; her D-positive newborn has a positive DAT and falling hemoglobin. Together, these findings warrant prompt review for possible immune hemolysis. For a separate hypothetical estimate, assume maternal blood volume is 5,000 mL and fetal cells account for 1%. Then 0.01 × 5,000 mL = 50 mL estimated fetal whole blood, subject to the sampling and method assumptions.

Watch the distinction: A positive DAT does not quantify newborn hemolysis, and a fetal-cell percentage does not prescribe treatment. Interpret each result with the other findings and stated assumptions.

10. How kidneys shape urine

Glomeruli filter water and small solutes from plasma, while tubules reclaim needed water and substances such as glucose and secrete selected ions and wastes. Urine composition therefore reflects both filtration and tubular handling. When circulating volume falls, intact kidneys can conserve water, producing concentrated urine while blood urea rises partly because more urea is reabsorbed. That pattern can support reduced renal perfusion, often called prerenal, but cannot establish its cause. Tubular injury may impair concentration and produce characteristic sediment findings; obstruction after urine formation creates a different, postrenal line of investigation. Compare urine concentration with serum results, clinical timing, and sediment rather than relying on one number. Osmotic solutes and some drugs can change urine concentration independently, so a concentrated or dilute specimen must be interpreted in context.

Worked example: After reported fluid loss, a patient's blood urea rises and urine remains highly concentrated by the supplied method. Preserved water conservation fits a prerenal pattern in this scenario. Check whether glucose or another osmotic solute could affect the measurement, then report the laboratory findings. The pattern alone cannot identify the source of fluid loss or establish a diagnosis.

Watch the distinction: Concentrated urine is not proof of a particular disease. It describes water handling and must be weighed against solutes, specimen timing, blood findings, and sediment.

11. Urine collection and stability

Collection method determines what a urine result can represent. A clean-catch specimen reduces external contamination; a timed collection requires every void within the defined interval plus accurate start and finish times. Examine a fresh specimen promptly or use the validated preservation and storage approach for the requested tests. Warm delay allows bacteria to multiply, consume glucose, and sometimes convert nitrate to nitrite; pH can rise as organisms metabolize constituents. Cells and casts may deteriorate, while light exposure can reduce light-sensitive analytes such as bilirubin. Refrigeration slows many changes but can precipitate crystals that were not visible when the urine was warm. Record collection and receipt times, storage conditions, and visible contamination. If deterioration undermines the requested interpretation, obtain a suitable replacement rather than reporting the altered result as representative.

Worked example: An unpreserved urine sample remains at room temperature for several hours before analysis. Its pH is higher than expected, nitrite is positive, and glucose is lower than a fresh comparison specimen. Bacterial growth could account for these changes, though the pattern does not prove contamination. Document the delay and follow the rejection or recollection procedure for the requested tests.

Watch the distinction: Refrigeration does not freeze urine composition in place. It slows deterioration but may create crystals, so collection time, storage, and warming instructions still matter.

12. Physical urine measurements

Color and clarity offer clues but are nonspecific: pigments, cells, organisms, crystals, and medications can each alter appearance. Specific gravity compares urine density with water and reflects both the number and mass of dissolved particles. A refractometer estimates it from refractive index, so substantial glucose or protein can raise the reading. A reagent-strip specific gravity pad mainly senses ionic strength and may disagree when large amounts of nonionic solute are present. Osmolality instead counts dissolved particles per kilogram of solvent; it better addresses particle concentration without giving the same weight to solute size. Compare methods only after checking calibration, temperature or instrument requirements, and specimen suitability. A disagreement can be informative rather than an automatic instrument failure. Link the physical finding to chemistry and sediment before inferring how the kidney handled water.

Worked example: A urine sample contains substantial glucose. Its refractometer specific gravity is high, while its strip estimate is lower. The refractometer responds to glucose's contribution to refractive index; the strip chiefly reflects ions. Check both methods' controls and the glucose result. If valid, the difference is expected from their measurement principles and does not require choosing one reading as universally correct.

Watch the distinction: Specific gravity and osmolality are related but not interchangeable. Large solutes can strongly affect refractometer specific gravity without changing particle count to the same extent.

13. Urine reagent-strip chemistry

Read each urine pad at its specified time and connect its chemical target to microscopy. The blood pad detects heme activity, so intact red cells, free hemoglobin, and myoglobin can all react. Protein pads are most sensitive to albumin; a negative pad does not exclude every protein. Glucose and ketone pads detect different products of carbohydrate metabolism, and common ketone chemistry misses some ketone species. Bilirubin is light sensitive, while urobilinogen has different interpretive limits. Nitrite requires suitable bacteria and enough bladder contact time; leukocyte esterase detects enzymes from white cells even when those cells have lysed. Urine pH can change during storage. Oxidizing contaminants, reducing substances, pigmentation, and improper timing may distort individual reactions. Resolve discordance by checking specimen quality, controls, sediment, and an appropriate confirmatory method.

Worked example: A fresh urine specimen has a strongly positive blood pad, but microscopy shows no intact red cells. Free hemoglobin, myoglobin, or red cells that lysed before examination could explain the reaction. Check collection and storage conditions, repeat or confirm as the method requires, and report the observed findings. The strip alone cannot distinguish hemoglobin from myoglobin.

Watch the distinction: A negative nitrite pad does not exclude bacteria. The organism may lack nitrate-reducing activity, or urine may not have remained in the bladder long enough.

14. Urine sediment clues

Urine sediment interpretation starts with preparation: mix the specimen, use a consistent centrifugation and resuspension method, and examine both low and high power fields. Red and white cells, epithelial cells, organisms, casts, and crystals carry different information. Casts form in renal tubules, so cells embedded within a cast localize the finding more strongly to the nephron than free cells do. Free red cells can enter urine anywhere along the tract or during collection. Crystals depend on pH, concentration, temperature, and storage; their presence alone seldom identifies a cause. Yeast can resemble red cells, while fibers or starch may mimic structures unless focus and morphology are checked. Correlate a blood-positive strip with red cells and casts, and assess contamination when squamous cells accompany apparent organisms. Refer uncertain or concerning structures for review.

Worked example: A well-prepared sediment shows a cylindrical matrix containing several embedded red cells, with additional free red cells in surrounding fields. The structure is a red-cell cast, which places at least part of the bleeding within the nephron. Free red cells alone would not provide that localization. Confirm the cast's morphology and report both the cast and hematuria for appropriate review.

Watch the distinction: Red cells near a cast are not necessarily embedded in it. Confirm that the cells lie within the cylindrical matrix before reporting a red-cell cast.

15. Timed urine calculations

A timed urine result combines concentration with the total volume collected over a known duration. Convert volume into the unit used by the concentration before multiplying: mg/dL times dL gives mg. For a 24-hour excretion, report mass per 24 hours only if the collection truly spans that interval. Clearance is a different calculation: urine concentration multiplied by urine flow rate, then divided by the matching plasma concentration, gives a volume of plasma cleared per unit time when the units align. A missed void lowers total measured excretion and can distort clearance; an incorrectly recorded duration changes the calculated flow rate. Compare collection notes and, where relevant, an expected excretion marker before interpreting the number. Laboratory staff verify arithmetic and collection plausibility but do not turn the result into a diagnosis.

Worked example: A hypothetical 24-hour urine collection contains 1.5 L at 40 mg/dL protein. Convert 1.5 L to 1,500 mL, then to 15 dL. Excretion is 40 mg/dL × 15 dL = 600 mg per 24 hours. If one void was missed, the measured 600 mg is an underestimate of the amount excreted during the full day.

Watch the distinction: Multiplying mg/dL by liters without conversion gives the wrong magnitude. Make the volume unit cancel the denominator, then check collection completeness.

16. Cerebrospinal fluid assessment

Cerebrospinal fluid has few cells under normal conditions and can change quickly after collection, so transport and processing are urgent. Allocate tubes according to the ordered microbiology, chemistry, and cell-count studies, preserving their sequence when comparing blood contamination. A traumatic collection can introduce peripheral red and white cells; fewer red cells in later tubes supports that explanation but does not settle every cause of bleeding. Examine cell counts and differential findings alongside appearance, chemistry, and collection notes. Delay can cause cell breakdown and weaken the reliability of a differential. A bloody specimen may also interfere with chemistry results, depending on method. Use the stated correction or interpretive approach only when its assumptions are provided. Escalate concerning counts or direct findings promptly while describing what the specimen supports and where collection limits remain.

Worked example: The first CSF tube is visibly bloody and has many red cells; the final tube has far fewer. The decline supports blood introduced during collection. Process the ordered studies promptly, record the tube sequence, and compare counts with chemistry and microbiology findings. Do not conclude from the decline alone that every other possible source of bleeding has been excluded.

Watch the distinction: A traumatic collection can alter counts, but it should not automatically explain all abnormal CSF findings. Review the full tube pattern and other tests.

17. Serous and synovial fluids

Serous fluids are interpreted with the fluid's site, appearance, cell count and differential, and paired serum chemistry when the method calls for it. Protein and LDH comparisons can describe whether fluid formation reflects a relatively low-protein fluid or a more inflammatory pattern, but specimen timing and supplied criteria matter. In synovial fluid, cell distribution and crystal examination add different evidence. Polarized light can distinguish crystals by shape and birefringence when the microscope setup and orientation are known. Needle-shaped, negatively birefringent crystals support monosodium urate identification; other crystals have different optical behavior. A crystal finding does not test for organisms or exclude simultaneous infection. Mix viscous fluid as required, check count dilution and chamber loading, and seek review for uncertain crystals. Report laboratory observations and arrange the ordered culture or additional testing.

Worked example: A synovial specimen shows needle-shaped crystals that are negatively birefringent under the stated compensated polarized-light setup. Report the observed crystals as consistent with monosodium urate. The same specimen has an elevated cell count under the supplied interval, so complete the ordered differential and microbiology work. Crystal identification does not rule out a concurrent infection.

Watch the distinction: Crystals and infection are not mutually exclusive. A convincing crystal observation does not justify omitting an ordered culture or dismissing concerning cell findings.

18. Other fluids and manual quality checks

Other body-fluid tests depend strongly on collection and method details. In semen analysis, incomplete collection or delayed examination can distort volume, concentration, and motility findings; report those limitations before interpretation. Fecal testing may be affected by sampling, diet or drugs under a particular method, and specimen contamination. Amniotic-fluid work likewise requires the stated collection, handling, and assay criteria rather than a generic interpretation. Manual chamber counts add analytical risks: wrong dilution, poor mixing, overfilled chambers, bubbles, or uneven cell distribution can produce misleading numbers. Verify the dilution factor and counting area before calculating a concentration. Microscopy preparation can create artifacts, while reagent strips require valid positive and negative controls read at the specified times. A failed control invalidates the patient result for that run, even when the patient result seems plausible.

Worked example: A fecal assay's positive control fails, while the patient sample reads negative. Because the run failed to detect a known positive, the patient negative is unsupported. Hold the result, investigate reagent condition, timing, and technique, then repeat the controls and patient sample on a valid run. Repeating only the patient sample with the same failed setup does not resolve the problem.

Watch the distinction: A plausible patient result does not rescue a failed control. Controls test whether the method could have detected the target in that run.

19. Chemistry specimen integrity

Chemistry begins with the right specimen: serum forms after clotting, plasma retains anticoagulant, and whole blood includes cells. A method validated for one may not accept another. Hemolysis releases intracellular constituents such as potassium and can alter optical readings. Lipemia scatters light and may affect some indirect measurements; icteric pigments can interfere with particular optical reactions. Delayed separation allows cells to consume glucose and exchange substances with plasma or serum. Additives can also create artifacts, such as contamination from a potassium-containing tube. Evaluate an unexpected result against specimen appearance, collection sequence, processing time, method-specific interference limits, and related analytes. Recollection may be necessary when interference exceeds a validated limit. In medical laboratory technician certification work, the key decision is whether the specimen can support the number the analyzer produced.

Worked example: A visibly hemolyzed serum specimen produces an unexpectedly high potassium result, while related results and the patient's earlier values do not fit. Cell rupture could have released potassium. Check the instrument's hemolysis assessment and the assay's validated interference limit. If the specimen exceeds that limit, hold the result and request recollection through the laboratory process rather than treating the number as confirmed hyperkalemia.

Watch the distinction: A numeric analyzer result is not automatically a valid patient concentration. Hemolysis can change the specimen before the assay measures it.

20. Glucose and long-term glycemia

Plasma glucose reflects concentration at collection only if cells are separated or glycolysis is controlled adequately. Continued cellular glucose consumption lowers a delayed, unseparated result. Ketone testing supplies complementary information about fat metabolism, but blood and urine methods may detect different ketone species. HbA1c reflects glucose exposure over red-cell life through nonenzymatic hemoglobin glycation; it is not a second measurement of the same momentary glucose value. Shortened red-cell survival gives hemoglobin less time to glycate and can lower HbA1c relative to actual exposure. Altered hemoglobin or a method-specific interference may also affect an assay. Compare collection timing, specimen handling, red-cell history, and the stated decision criteria before interpreting discordant results. Report the laboratory pattern and its limitations; diagnosis and treatment decisions require the care team's broader assessment.

Worked example: Two glucose specimens come from the same draw. One is separated promptly; the other remains unseparated for several hours and reads lower. Ongoing glycolysis in the delayed tube explains the direction of the difference, so the promptly processed result better represents collection time. If the patient also has shortened red-cell survival, a relatively low HbA1c may understate prior glucose exposure.

Watch the distinction: A low HbA1c does not always contradict a high glucose result. Recent glucose and glycation over red-cell survival answer different questions.

21. Lipids and serum proteins

A calculated LDL cholesterol value depends on the formula and the specimen conditions specified with the result. In the common mg/dL relationship, triglycerides divided by five estimate cholesterol carried in very low density lipoproteins; the divisor is an assumption, not a direct measurement. Check whether the method permits that calculation for the specimen before interpreting it. Serum protein results require a different kind of comparison. Total protein combines albumin and globulins, while electrophoresis shows how protein is distributed among fractions. Increased concentration can follow water loss even when protein mass has not increased. Low albumin may reflect loss, reduced production, dilution or inflammation. A narrow abnormal electrophoretic band raises a different question from a broad inflammatory increase and needs appropriate characterization. Compare patterns with specimen quality and other results rather than assigning a diagnosis from one number.

Worked example: Suppose the stated formula is LDL = total cholesterol − HDL − triglycerides/5, with all values in mg/dL. At 200, 50 and 150 mg/dL, estimated LDL is 200 − 50 − 30 = 120 mg/dL. The arithmetic is valid only if the method's triglyceride and specimen conditions permit the estimate. If albumin is also high after fluid loss, consider concentration from reduced plasma water before inferring increased protein production.

Watch the distinction: A calculated LDL value is not a direct LDL measurement. Its reliability depends on the formula's assumptions; likewise, a high protein concentration can reflect reduced water rather than excess protein production.

22. Renal markers and electrolytes

Urea nitrogen reflects protein metabolism as well as renal excretion, so intake, catabolism and water balance can change it. Creatinine is produced from muscle and cleared largely through the kidneys; muscle mass and some assay interferences affect its interpretation. Read both alongside collection history, trends and any supplied renal estimate. Sodium mainly reflects water balance relative to dissolved sodium, whereas potassium is vulnerable to release from damaged blood cells during collection or processing. Calcium interpretation may depend on albumin when total calcium is measured; ionized calcium answers a different question. The anion gap compares routinely measured ions to reveal an imbalance in unmeasured charged particles. Use the laboratory's stated equation and interval, since included ions and methods vary. Check hemolysis and other specimen problems before giving a biochemical pattern undue weight.

Worked example: Use the supplied equation Na − (Cl + bicarbonate) and a hypothetical interval of 8–16 mmol/L. With Na 140, Cl 104 and bicarbonate 22 mmol/L, the gap is 140 − (104 + 22) = 14 mmol/L, within that interval. A potassium result from the same visibly hemolyzed tube needs separate review because released cellular potassium could raise it without a matching patient change.

Watch the distinction: A raised urea result alone does not establish impaired filtration. Production and water balance also affect urea, while hemolysis can make potassium appear high despite an otherwise plausible chemistry panel.

23. Blood gases and acid-base balance

Start an acid–base assessment with pH: a low pH indicates acidemia and a high pH alkalemia under the supplied interval. Next compare carbon dioxide pressure, the respiratory component, with bicarbonate, the metabolic component. Increased PCO2 pushes pH downward; decreased bicarbonate also pushes it downward. The variable moving in the direction that explains the pH suggests the primary disturbance. Compensation is the body's response through the other component, but deciding whether it is appropriate requires a stated expectation and attention to timing. A near-normal pH can conceal two opposing disturbances. For specimen review, confirm arterial or venous origin, collection time and handling. Ongoing cellular metabolism during delay changes gases and pH; exposure to room air can alter measured gases. Report the measured pattern and investigate inconsistent specimens before attaching a clinical interpretation.

Worked example: A hypothetical arterial sample has pH 7.28, PCO2 55 mmHg and bicarbonate 25 mmol/L; the supplied pH interval is 7.35–7.45. The pH shows acidemia. Raised PCO2 explains its direction, while bicarbonate is not decreased, so the primary pattern is respiratory acidosis. Without a supplied compensation rule, do not classify compensation more precisely. Confirm collection type and prompt analysis before release.

Watch the distinction: An abnormal bicarbonate does not automatically identify the primary disorder. Determine acidemia or alkalemia first, then compare PCO2 and bicarbonate; specimen delay can also distort the apparent pattern.

24. Tissue injury markers

A tissue marker becomes detectable when its source releases it, but its concentration also depends on the time since injury, clearance and assay behavior. Bilirubin is produced during heme breakdown, processed by the liver and excreted in bile; comparing conjugated and unconjugated fractions helps locate a broad processing or excretion pattern. Liver-associated enzymes differ in tissue distribution, so a single elevation has limited specificity. Pancreatic enzymes likewise require attention to timing and other sources. For cardiac biomarkers, serial values are often more informative than one value because a change may reveal evolving injury. Confirm that successive samples used comparable methods and note each collection time. Hemolysis, interference and results near an assay's measurement limit can weaken a trend. The technician reports valid measurements, checks unexpected changes and promptly escalates results meeting the supplied notification rule.

Worked example: Suppose a cardiac marker measures 8 ng/L at 08:00 and 34 ng/L at 12:00 on the same assay, and the supplied rule flags a rise greater than 20 ng/L. The change is 34 − 8 = 26 ng/L, so it meets that hypothetical flag. Verify both specimen times and analytical validity, then report and escalate the trend as required. It identifies a laboratory change, not its cause.

Watch the distinction: One normal early cardiac marker cannot exclude a later rise. Collection timing, assay limits and serial change matter; an elevated marker also cannot independently establish the clinical cause of injury.

25. Endocrine feedback and timing

Endocrine interpretation begins with the direction of feedback. When circulating thyroid hormone falls, an intact pituitary response generally raises TSH; a mismatch calls for assessment of the feedback pathway and assay reliability. Cortisol, ACTH and several reproductive hormones vary with time of day or physiologic phase, so a concentration without collection context can mislead. Stimulation and suppression testing ask whether a gland responds to a defined challenge; the administered agent, baseline sample and timed samples must match the stated protocol. Immunoassays add another layer: binding antibodies, high-dose effects or supplements can produce results that conflict with related hormones or prior measurements. Review identifiers, units, collection time, medication history available to the laboratory and assay flags. The technician can recognize and investigate a discordant pattern without turning that pattern into a clinical diagnosis.

Worked example: A hypothetical report gives free thyroxine 0.6 ng/dL against a supplied interval of 0.8–1.8, and TSH 12 mIU/L against 0.4–4.0. Low free thyroxine with high TSH fits a feedback response to reduced thyroid hormone. If the patient previously had a markedly different TSH, verify specimen identity and consider method interference before finalizing the laboratory interpretation.

Watch the distinction: An isolated hormone value may be uninterpretable without collection timing or the paired feedback hormone. A discordant immunoassay result can persist on simple repeat testing if the same interference remains.

26. Iron, nutrition and drugs

Iron studies answer related but distinct questions. Serum iron measures circulating iron bound to transferrin and can vary with collection conditions; transferrin or total iron-binding capacity reflects transport capacity; ferritin generally reflects stored iron but can also rise with inflammation. Read the combination with blood counts and specimen quality. Nutritional markers such as vitamin B12 and folate support an investigation but do not replace the blood-cell pattern or method limits. For therapeutic drug monitoring, a concentration has meaning only relative to dose, collection time, dosing history and the supplied target interval. A peak and a trough sample answer different questions, and a mistimed sample should be labeled accordingly. Toxicology immunoassays are often screens: cross-reactivity may yield a positive result that needs a more specific confirmatory method under the stated testing pathway.

Worked example: A drug was given at 08:00, but a sample labeled trough was drawn at 08:30. A supplied trough interval applies immediately before the next dose, so this result cannot be judged against it. Record the actual times and flag the timing mismatch. Separately, low ferritin with low serum iron and high binding capacity supports depleted iron stores more strongly than serum iron alone.

Watch the distinction: A drug value inside a stated trough interval is not reassuring if the sample was drawn after dosing. Collection time defines the comparison; a positive toxicology screen also remains a screening finding.

27. Analytical methods and limits

Analytical methods turn different physical events into numbers. Spectrophotometry measures light absorbed by a reaction product; ion-selective electrodes respond to ionic activity; electrophoresis and chromatography separate components before measurement; immunoassays detect binding through a labeled or optical signal. Their interferences differ, so first identify the method behind an unexpected result. Calibration establishes the relationship between signal and concentration, while quality controls test whether a run behaves acceptably. A result above the analytical measurement range cannot simply be extrapolated. A validated dilution may bring it into range, after which the measured value is multiplied by the total dilution factor and checked against the permitted reporting range. American Society for Clinical Pathology provides the issuer's certification entry point; laboratory decisions here depend on the assay's validated limits. Further MLT(ASCP) practice questions can reinforce method-based reasoning.

Worked example: A specimen is mixed as one part sample plus three parts diluent, a 1:4 dilution. The diluted sample reads 30 U/L on a valid run, giving 30 × 4 = 120 U/L in the original sample. Confirm that 30 U/L lies within the assay's measurement range and that this fourfold dilution is validated before reporting 120 U/L. Passing controls alone cannot validate an unapproved dilution.

Watch the distinction: A dilution factor counts total parts, not added diluent alone. One part sample plus three parts diluent requires multiplication by four, provided the method validates that dilution.

Reference: [1]

28. Blood-cell production

Peripheral counts reflect production, release, survival and distribution, not marrow output alone. Red cells mature from nucleated precursors into reticulocytes and then circulating erythrocytes; reticulocytes therefore offer a view of recent red-cell production. In anemia, a raw reticulocyte percentage can appear high partly because fewer mature red cells remain, so compare it with the hematocrit or use a supplied correction. Neutrophils respond rapidly to inflammatory demand, whereas lymphocytes coordinate adaptive responses; shifts can also reflect redistribution. Platelets arise from megakaryocytes and participate in primary hemostasis. When a count is low, ask whether production is reduced, cells are being consumed or destroyed, or an analytical artifact is present. Smear findings and serial counts help separate these possibilities. The MLT recognizes laboratory response patterns and routes suspicious findings for appropriate review.

Worked example: Two hypothetical patients each have a hematocrit of 24%. Patient A has reticulocytes at 6%; patient B has 0.5%. Using a supplied reference hematocrit of 45%, corrected reticulocytes are 6 × 24/45 = 3.2% for A and 0.5 × 24/45 ≈ 0.27% for B. A shows a greater marrow response; B's response is limited. Neither figure alone establishes why anemia developed.

Watch the distinction: A high reticulocyte percentage does not always mean adequate production. In anemia, the smaller mature red-cell pool inflates that percentage; correct or contextualize it before comparing responses.

29. Counting methods and artifacts

Impedance counters register electrical changes as cells pass through an aperture and primarily infer size from pulse magnitude. Optical methods measure light scatter and, in some systems, fluorescence to distinguish populations. Both methods can misclassify particles that overlap in size or signal. Platelet clumps may be excluded as large particles and produce a falsely low platelet count; small red-cell fragments can create a different interference. Cold agglutination may lower the apparent red-cell count while distorting calculated indices. Histograms reveal unusual size distributions, and scattergrams show whether populations separate as expected. Treat an analyzer flag as a prompt to inspect the result, prior values and a properly prepared smear. If an artifact is confirmed, follow the validated repeat or alternative counting approach and document the limitation before reporting.

Worked example: An EDTA sample yields platelets of 42 × 10^9/L with a clump flag. The smear shows large aggregates near its feathered edge, so the automated count may be falsely low. Check the specimen for clotting and use the laboratory's approved recollection or alternative method. A repeat number from the same clumped tube, without resolving the interference, does not establish the patient's count.

Watch the distinction: An analyzer flag is neither a diagnosis nor permission to discard the result. It identifies a possible measurement problem that must be checked against the specimen and smear.

30. Red-cell indices and counts

Red-cell indices connect measured count, hemoglobin and hematocrit to average cell properties. With RBC in millions per microliter, hematocrit as a percentage and hemoglobin in g/dL, MCV = hematocrit × 10/RBC in femtoliters; MCH = hemoglobin × 10/RBC in picograms; MCHC = hemoglobin × 100/hematocrit in g/dL. Each index answers a different question: cell volume, hemoglobin mass per cell and hemoglobin concentration within packed red cells. Check that the underlying measurements agree before interpreting indices. For example, an implausible MCHC or an unusual mismatch among RBC count, hematocrit and hemoglobin can point to cold agglutination, lipemia or another interference. Absolute white-cell counts similarly require multiplying the total WBC by a differential fraction. Use a related MLS study guide for further laboratory context while keeping the calculation tied to the supplied MLT case.

Worked example: For hypothetical RBC 4.0 million/µL, hematocrit 30% and hemoglobin 10 g/dL, MCV = 30 × 10/4.0 = 75 fL, MCH = 10 × 10/4.0 = 25 pg, and MCHC = 10 × 100/30 ≈ 33.3 g/dL. The first two values support smaller cells with less hemoglobin per cell. Compare the pattern with the smear and supplied intervals.

Watch the distinction: MCH and MCHC are not interchangeable. MCH describes hemoglobin mass per cell; MCHC describes its concentration in packed red cells, so they can tell different stories.

31. Red-cell morphology

Read a red-cell smear systematically: judge size, central pallor, variation, shape and inclusions in a suitable monolayer. Small cells with expanded central pallor are microcytic and hypochromic; large cells raise a different set of production questions. Marked size variation can explain a high red-cell distribution width, while polychromasia often reflects circulating reticulocytes. Shape findings add clues but require context: fragments can accompany mechanical destruction, target cells occur in several conditions, and spherocytes have more than one cause. Inclusions can point toward altered hemoglobin, organelle remnants or other cell processes, depending on their appearance and staining. Correlate morphology with indices, reticulocytes and relevant chemistry. Poor smear thickness, drying or stain quality can imitate abnormalities, so confirm that the field and preparation support the observation before recording it.

Worked example: A hypothetical CBC reports MCV 72 fL, and the smear shows many small cells with broad central pallor and marked size variation. Together these support a microcytic, hypochromic pattern with anisocytosis. Low ferritin would favor depleted iron stores; if ferritin is not low, other causes remain open. Report the morphology and relevant discrepancy rather than labeling the patient from the smear alone.

Watch the distinction: Microcytosis does not uniquely identify iron deficiency. Similar cell size can arise through different mechanisms, and poor smear preparation can exaggerate pallor or distort shapes.

32. White-cell differential

A differential percentage describes the share of counted white cells, not their concentration in blood. Multiply the total WBC by each fraction to obtain an absolute count, then compare it with the supplied interval. On a smear, mature neutrophils have segmented nuclei and characteristic granules; bands and earlier precursors require careful distinction from reactive changes and artifacts. Reactive lymphocytes can vary widely in shape, while a suspicious uniform abnormal population needs review under the laboratory pathway. Count cells in an appropriate monolayer and watch for uneven distribution, especially large cells near the smear edge. Analyzer flags guide where to look but do not replace morphology. A plausible absolute neutrophil count also does not settle whether unexpected immature cells are present. Document the observed cells and route findings beyond technician authorization for supervisory or pathologist review.

Worked example: A hypothetical WBC is 12.0 × 10^9/L with 70% neutrophils. The absolute neutrophil count is 12.0 × 0.70 = 8.4 × 10^9/L. The smear also contains a few cells with immature features that the analyzer flagged. Calculate and report the count through the validated workflow, but arrange the specified morphologic review; the numeric result does not resolve those cells' identity.

Watch the distinction: Seventy percent neutrophils does not mean 70 × 10^9/L. Multiply the fraction, 0.70, by the total WBC, and assess suspicious morphology separately.

33. Platelets and selected manual tests

Platelet assessment combines the analyzer count with smear distribution and morphology. Small platelets, giant platelets and aggregates may produce different counting biases; clumps often collect near the feathered edge, so inspect more than one area. A smear estimate is useful as a reasonableness check only when the preparation and method support it. Manual differentials require an even monolayer and a defined counting approach; counting thick areas distorts cell identification. Reticulocyte methods depend on adequate mixing and stain performance. Special stains require working controls because a weak patient reaction cannot be trusted when the reagent fails. A chamber count adds dilution, chamber depth and grid-selection steps, each capable of producing systematic error. When manual and automated findings disagree, identify the likely failure point, document it and repeat with a validated method before releasing an unsupported number.

Worked example: An analyzer reports platelets of 38 × 10^9/L, but the smear shows numerous aggregates at the feathered edge and otherwise visible platelets in the monolayer. Clumping can remove platelets from the analyzer's platelet gate, making 38 × 10^9/L unreliable. Record the finding and follow the approved repeat-count method. Do not turn an informal smear impression into an exact replacement count.

Watch the distinction: A smear estimate cannot repair every flagged platelet count. Aggregates make both the automated count and a routine field estimate unreliable until the collection or counting problem is resolved.

34. Hemostasis screening patterns

Primary hemostasis forms a platelet plug at the injury site. Coagulation then generates thrombin and fibrin to stabilize it, while fibrinolysis removes fibrin as healing proceeds. Screening tests sample different parts of this process. PT is sensitive to the tissue factor pathway and shared factors; aPTT samples contact-activated and shared factors. Thrombin time focuses on conversion of fibrinogen to fibrin and can be affected by some anticoagulants or fibrinogen abnormalities. A fibrinogen assay estimates available functional substrate, while D-dimer reflects breakdown of cross-linked fibrin but has limited specificity for cause. Interpret patterns with the supplied reference intervals, medication and specimen history. An isolated prolongation narrows the next investigation; it does not name a factor. Mixing studies and specific assays can distinguish deficiencies from inhibitors or drug effects.

Worked example: Suppose PT is 12 seconds within a supplied interval of 10–14, while aPTT is 54 seconds against 25–35. Only aPTT is prolonged. Consider a factor deficiency affecting that assay, an inhibitor or an anticoagulant effect; first check tube quality and drug information. A properly designed mixing study may help separate these patterns. The two screening times alone cannot identify a specific factor.

Watch the distinction: A prolonged aPTT does not automatically mean hemophilia. Inhibitors, anticoagulants and specimen problems can produce the same screening pattern and require different follow-up.

35. Mixing studies and inhibitors

A mixing study combines patient plasma with normal plasma, commonly in equal parts, and tests whether the added normal factors restore clotting. Correction suggests that a factor deficiency may be present because the mixture supplies what the patient sample lacks. Persistent prolongation suggests inhibition or an anticoagulant effect, since the added factors do not overcome it. Some inhibitors act gradually, so compare the immediate mixture with one incubated under the stated conditions. Interpretation depends on the laboratory's correction definition; dilution of an inhibitor can sometimes make an immediate mixture look corrected. Heparin contamination and other drugs must also be considered before assigning a mechanism. The technician checks specimen suitability, follows the timed procedure, records both results and directs the pattern to factor-specific, inhibitor or drug testing as indicated.

Worked example: A hypothetical aPTT is 65 seconds, with a supplied normal interval of 25–35. After 1:1 mixing, it is 34 seconds immediately but 58 seconds after the specified incubation. Under a stated rule that 34 seconds counts as correction, the immediate result corrects and the incubated result loses correction. This time-dependent pattern suggests an inhibitor; specific testing is still needed to characterize it.

Watch the distinction: Immediate correction does not rule out an inhibitor. A time-dependent inhibitor may allow a normal early mixture and prolong it after incubation, while drug effects can complicate interpretation.

36. Coagulation specimen reliability

Coagulation tubes depend on a controlled citrate-to-plasma ratio. Citrate binds calcium during storage; the analyzer then adds calcium back to start the reaction. Underfilling leaves too much citrate for the available plasma and can falsely prolong clotting times. A markedly increased hematocrit reduces plasma volume even in a filled tube, so the stated procedure may require citrate adjustment. A clot, poor mixing or processing delay can consume or alter factors. Drawing through a heparinized line can introduce anticoagulant and mimic a patient abnormality. Before interpreting an unexpected PT or aPTT, inspect tube fill, sample condition, collection source, timing and relevant quality controls. Recollection is often the cleanest resolution when the specimen cannot support a valid result. Document the reason and avoid treating an artifact as a patient's coagulation status.

Worked example: A citrate tube is visibly below its intended fill mark and produces an aPTT of 61 seconds against a supplied interval of 25–35. Because excess citrate relative to plasma can bind more of the calcium added during testing, the prolongation may be artifactual. Hold the result and follow the laboratory's rejection or recollection procedure. The value cannot establish an inhibitor from this specimen.

Watch the distinction: An abnormal coagulation time from an underfilled tube is not reliable evidence of disease. The citrate-to-plasma ratio changes the reaction itself, so repeating the same flawed specimen may reproduce the error.

37. Immune system foundations

Innate defenses respond quickly through barriers, phagocytes and complement; adaptive immunity adds antigen-specific B and T cells. B cells can become plasma cells that secrete antibodies or memory cells that support a faster response on re-exposure. IgM often appears early in a primary response, while class-switched IgG commonly dominates a later response. IgA protects mucosal surfaces, IgE participates in allergic and parasite responses, and IgG has major roles in circulation and immune memory. Complement can mark targets for phagocytosis, recruit inflammatory cells and, in some settings, damage membranes. T cells coordinate responses or kill infected cells without secreting immunoglobulin. Laboratory measurements each cover only part of this system: a total immunoglobulin concentration does not directly demonstrate antigen-specific function, and a complement concentration alone does not prove that the pathway works normally.

Worked example: In a hypothetical paired history, the first exposure produces a slow IgM rise followed by modest IgG. On later exposure to the same antigen, IgG rises earlier and higher. Memory B cells and class switching explain the pattern. If total IgG is within its supplied interval, that does not prove every antigen-specific response is effective; the paired response supplies more functional information.

Watch the distinction: A normal total-IgG result does not prove normal immune competence. It measures quantity across many antibodies, while protection also depends on specificity, memory, cellular responses and complement function.

38. Antigen-antibody reaction limits

Antibody binding depends on affinity at one binding site and avidity across all binding contacts. Cross-reactivity occurs when an antibody recognizes similar structures on different targets, so a positive reaction can have more than one explanation. Visible lattice formation also needs a workable antigen-to-antibody balance. In antibody excess, a prozone effect can prevent efficient cross-linking; in antigen excess, a postzone effect can do the same. Either may make a truly reactive sample appear weak or negative in an agglutination or precipitation method. When the clinical and analytical context conflicts with a neat result, use the assay's validated dilution sequence and controls. A dilution-dependent increase can reveal prozone, but dilution also changes many interactions, so confirm the pattern rather than declaring the mechanism from one tube. Record the endpoint and any method limitation.

Worked example: A hypothetical agglutination assay is negative on the neat specimen, positive at 1:4 and 1:8, then negative at 1:32; controls pass. Reactivity appearing after dilution is compatible with antibody excess in the neat sample. Repeat the validated series to confirm the result and endpoint. The negative 1:32 tube is expected once dilution reduces reactive antibody below detection.

Watch the distinction: A negative neat reaction does not always mean the target is absent. Antibody excess can prevent visible lattice formation; validated dilutions and controls can reveal the hidden reaction.

39. Immunoassay signal patterns

Immunology assays differ both in what produces a signal and how signal relates to analyte concentration. Agglutination shows particle clumping; precipitation forms soluble-antigen antibody lattices. Nephelometry measures scattered light, while turbidimetry measures light lost through a cloudy mixture. Immunofluorescence reads emitted light from a fluorescent label. Enzyme and chemiluminescent assays convert labeled binding into color or light. In a sandwich assay, more captured analyte usually binds more detection label, so signal rises with concentration within the validated range. In a competitive assay, sample analyte competes with labeled analyte for limited binding sites, often making signal fall as analyte rises. Read the assay design before interpreting a high or low signal. Controls, calibration and high-dose effects remain relevant even when the signal direction is understood.

Worked example: In a stated competitive assay, unlabeled patient analyte and labeled analyte compete for the same antibody sites. Sample A produces 800 light units; sample B produces 300, with valid calibration showing inverse signal. B therefore contains more analyte than A, although an exact concentration requires the calibration curve. In a stated sandwich assay with direct signal, the ordering would generally be reversed.

Watch the distinction: A stronger signal does not always mean more analyte. Competitive assays can produce an inverse relationship, so identify the binding design and calibration before interpreting the instrument signal.

40. Immunology controls and interference

Controls answer whether an assay run performs acceptably at known concentrations, but they cannot reveal every patient-specific interference. Calibration establishes the signal-to-concentration relationship; a shift can move many results together, whereas heterophile antibodies or other nonspecific binding may affect one specimen. Reagent deterioration, incorrect storage and wash problems can increase background or weaken signal. When a result conflicts with prior values and related tests, first verify identity, units, timing, instrument flags and control status. Then choose an investigation suited to the suspected mechanism: a validated blocking reagent, serial dilution for nonlinearity, or comparison on an alternative platform. An apparently normal repeat on the same method may leave the original interference intact. Document the investigation and seek authorized review before releasing a corrected or qualified interpretation.

Worked example: A hormone result is 90 units against a prior stable range of 8–12 units, while current controls pass and the paired hormone pattern conflicts. Repeating the specimen gives 88 units, so random error is less likely, but interference remains possible. A validated blocking step yields 11 units and an alternative method gives 10 units. The discrepancy supports investigating assay interference before the original value is reported as genuine.

Watch the distinction: Passing controls do not guarantee that every patient specimen is free of interference. Heterophile binding can affect one sample while routine controls and repeated measurements appear consistent.

41. Infectious serology

Infectious serology depends on both the target and the time since exposure. An antigen or organism-specific nucleic-acid test can become positive before the immune system produces enough antibody for detection. IgM may suggest a recent response in some assays, while IgG may persist after recovery or vaccination; neither interpretation is safe without the organism-specific algorithm. For hepatitis B, for example, surface antigen, surface antibody and core antibody answer different questions about current antigen detection and immune history. A reactive screening result may require a different confirmatory method, and a negative antibody screen during the window period cannot exclude recent infection. Check specimen timing, assay target, controls and any prior results before reporting. Follow the supplied testing sequence and communicate results as laboratory evidence rather than a definitive clinical diagnosis.

Worked example: A patient provides serum shortly after a possible exposure. The antibody screen is negative, and the case algorithm calls for a nucleic-acid test when exposure is recent. The technician records the collection timing and performs or routes that test. If it is also negative, the result describes what was detectable in this specimen; the stated repeat interval still applies because early infection may escape both tests.

Watch the distinction: A negative antibody test immediately after exposure does not prove the patient was never infected. Antibody production takes time, so interpret the result with the assay's window and the specified follow-up sequence.

42. Autoimmunity and inflammation

Autoantibody and inflammation tests answer related but different questions. An antinuclear-antibody screen detects binding to nuclear targets, but a positive screen can occur in several conditions and in people without a defined autoimmune disease. Its pattern and titer may guide a specified reflex panel; they do not identify a diagnosis alone. Rheumatoid factor also lacks disease specificity. C-reactive protein and erythrocyte sedimentation rate reflect inflammation through different mechanisms, so a raised value does not locate its cause. Complement measurements add another clue: reduced components can reflect consumption in an active immune process, though production and other losses also matter. Check the method, reference interval, prior results and specimen quality. Report the measured findings and flag results requiring review, leaving the clinical synthesis to the authorized clinician.

Worked example: A specimen has a positive ANA screen, raised C-reactive protein and low C3 against the supplied intervals. The pattern supports further investigation of an immune or inflammatory process, but it does not name one. The technician verifies controls, records the ANA pattern and titer if required, and routes the sample for the specified reflex antibodies. The clinician interprets those results with the patient's findings.

Watch the distinction: Treating a positive ANA as proof of a particular disease ignores its limited specificity. Reflex antibody results, titer, method and clinical context are needed to narrow the possibilities.

43. Titers and paired specimens

A titer is the reciprocal of the greatest dilution that still meets the assay's reaction criterion. In a twofold series, each well halves the antibody concentration: 1:2, 1:4, 1:8 and so on. The endpoint depends on the reagent, reading rule and specimen handling, so paired samples should be tested by the same method, ideally in the same run. Count the dilution steps to compare endpoints; two steps equal a fourfold change. A rise may support a recent immune response when collection timing and the supplied significance rule fit. A fall may reflect a waning response, but antibodies can persist and some tests are not designed for monitoring. Record the actual endpoint and any dilution beyond the validated series. A titer is an assay endpoint, not a direct concentration measurement.

Worked example: Two serum specimens collected at the stated interval are tested together by the same twofold method. The first reacts through 1:8 but not 1:16; the second reacts through 1:32 but not 1:64. The titers are 8 and 32. The endpoint increased 32 ÷ 8 = 4-fold, or two dilution steps. It meets a hypothetical rule requiring a fourfold rise, provided both runs pass controls.

Watch the distinction: Comparing a 1:8 endpoint from one method with 1:32 from another can create a false trend. Endpoint differences are meaningful only when methods, reading criteria and collection timing support comparison.

44. Predictive value

Sensitivity is the fraction of people with the target condition who test positive; specificity is the fraction without it who test negative. Positive predictive value asks a different question: among positive results, how many are true positives? Negative predictive value uses all negative results as its denominator. Predictive values change with prevalence because the mix of people being tested changes, even when sensitivity and specificity stay constant. In a low-prevalence group, false positives can outnumber true positives. Build a two-by-two table before calculating: true positives and false negatives form the condition-present group; false positives and true negatives form the condition-absent group. A screening result may therefore require a separate confirmation pathway. For more case practice, use the MLT(ASCP) practice questions.

Worked example: In a hypothetical group, 100 people have the condition: 80 test positive and 20 negative. Of 900 without it, 90 test positive and 810 negative. Sensitivity is 80/100 = 80%; specificity is 810/900 = 90%. Positive predictive value is 80/(80 + 90) = 47.1%, while negative predictive value is 810/(810 + 20) = 97.6%. Follow the supplied confirmation pathway for positive screens.

Watch the distinction: A test with 90% specificity does not mean 90% of its positive results are correct. That latter fraction is positive predictive value, which also depends on condition prevalence.

45. Microbiology specimen choice

Specimen choice determines what a microbiology result can mean. Material from the actual site of suspected infection is more informative than material collected from a colonized surface. A deep aspirate or tissue sample may preserve organisms that a superficial swab misses and can better support an anaerobic workup. Anaerobes may lose viability during air exposure, while other targets require different transport media or temperatures. Prior antimicrobial treatment can reduce culture recovery even when microscopy or molecular testing detects evidence of an organism. At receipt, check patient identity, site, collection method, container, time and transport conditions. Then decide whether the specimen meets the method's acceptability criteria, needs a qualified report or requires recollection. Mixed growth from a poorly collected sample should not be promoted automatically to evidence of deep infection.

Worked example: A superficial wound swab for suspected deep anaerobic infection arrives after prolonged air exposure. It samples organisms on the surface, and the exposure may have reduced viable anaerobes. The technician documents both limitations and follows the rejection or qualified-processing procedure. A properly collected deep aspirate in suitable anaerobic transport would better address the request. Any urgent finding is still escalated through the laboratory's authorized route.

Watch the distinction: Growth of an organism from a wound swab does not establish that it caused a deep infection. Specimen depth, contamination risk and transport conditions govern how strongly growth can be interpreted.

46. Direct stains and culture

Direct stains give rapid structural clues, while culture tests whether organisms can grow under selected conditions. In a Gram stain, the staining sequence separates organisms that retain crystal violet from those counterstained pink; cell shape and arrangement add clues, but staining age and technique can distort them. Acid-fast stains exploit the waxy cell envelope of certain organisms and require a separate identification pathway. Selective media suppress some competitors; differential media reveal biochemical behavior, such as lactose fermentation. Incubation atmosphere and duration determine what can be recovered. First judge specimen quality, then read the direct smear, choose appropriate media and compare growth with the smear. Stain controls and media performance checks matter: a failed control can make an apparent absence or identity clue unreliable. Neither stain nor colony appearance alone establishes species.

Worked example: A sputum Gram stain contains many squamous epithelial cells, few inflammatory cells and several bacterial shapes. Squamous cells point to oral contamination, and the mixed forms offer no clear lower-respiratory target. The technician applies the stated acceptability rule before interpreting culture growth. If the sample is rejected, a better collected specimen is requested; if processed with qualification, the report preserves the contamination limitation.

Watch the distinction: Mixed growth on culture does not override a poor sputum smear. When oral material dominates collection, recovered organisms may represent mouth flora rather than the lower-respiratory process under investigation.

47. Gram-positive identification

Start gram-positive identification with morphology and arrangement, then test a branch point with valid controls. Cocci in clusters suggest staphylococci; catalase positivity supports that branch, whereas catalase-negative cocci often lead toward streptococci or enterococci. Coagulase or a validated equivalent helps distinguish Staphylococcus aureus from many other staphylococci. Hemolysis on blood agar is useful for streptococcal workups but does not identify a species by itself. Gram-positive bacilli require a different sequence that may include spore formation, motility and growth conditions. Interpret each result only in a pure, suitable isolate; mixed colonies can combine reactions from different organisms. Check reagent controls and the test's reading time before using a negative reaction. Escalate unusual or potentially hazardous isolates according to the laboratory's identification and safety procedures.

Worked example: A pure colony yields gram-positive cocci in clusters, a positive catalase reaction and a positive coagulase result. Positive and negative reagent controls behave as expected. Under the stated identification method, that combination supports Staphylococcus aureus. If the coagulase positive control had failed, the isolate's coagulase result would be invalid; the technician would correct the test problem before final identification.

Watch the distinction: Calling every cluster-forming gram-positive coccus Staphylococcus aureus skips the key discriminating test. Arrangement narrows the workup, while valid catalase and coagulase findings support the identification.

48. Gram-negative and anaerobic workups

Growth pattern directs the next gram-negative or anaerobic workup. Enteric media help recover many gram-negative bacilli and show reactions such as lactose fermentation. Lactose-positive growth narrows possibilities but does not identify one organism. Nonfermenters may use carbohydrates differently, often requiring oxidase and validated identification results. Fastidious organisms may need enriched media, a particular atmosphere or growth factors, so failure on routine enteric plates is not proof of absence. For suspected anaerobes, begin with a suitable deep specimen protected from oxygen; compare aerobic and anaerobic growth and confirm purity before biochemical or instrument identification. An isolate growing only anaerobically supports that pathway, but specimen contamination and aerotolerance remain considerations. Combine culture features with the direct stain and source, and investigate discordant results before release.

Worked example: Two isolates are recovered from separate acceptable specimens. Isolate A grows on enteric medium and ferments lactose, so the technician proceeds with the validated enteric identification panel; lactose alone cannot assign a species. Isolate B grows anaerobically but not on paired aerobic plates, directing an anaerobic workup. If B came instead from a superficial swab, the report would need the specimen-quality limitation before assigning clinical significance.

Watch the distinction: An organism that fails to grow aerobically is not identified simply as an anaerobic pathogen. Confirm viable growth, check culture conditions and specimen quality, then use the validated identification pathway.

49. Mycobacteria and fungi

Mycobacterial and fungal investigations use different processing and safety decisions from routine bacterial culture. A mycobacterial specimen may be concentrated and treated to reduce competing flora before acid-fast staining and prolonged culture. An acid-fast smear detects organisms with the staining property, not a species or necessarily viable cells; molecular or culture identification adds specificity. Slow growth means a negative routine plate is uninformative for this target. Fungal examination compares budding yeasts, hyphae or other structures with culture and validated identification data. Some molds and dimorphic fungi pose exposure risks when manipulated, so a suspicious culture must be handled through the laboratory's containment or referral pathway. Check specimen source and stain controls, report preliminary observations accurately, and avoid turning a morphological clue into a definitive identification.

Worked example: A respiratory specimen is acid-fast smear positive, while routine bacterial plates show no corresponding growth. The technician records the smear finding and routes the specimen for the specified mycobacterial molecular and culture workup under the required containment procedure. The routine plates do not refute the smear. Until identification testing is complete, the finding supports an acid-fast organism, not a particular mycobacterial species.

Watch the distinction: A positive acid-fast smear is not synonymous with tuberculosis. The stain detects a property shared by multiple organisms, so species identification requires the appropriate follow-up method.

50. Parasites and viruses

Detection succeeds when the specimen contains the life stage or viral target the method measures. Parasite eggs, cysts, trophozoites and blood stages appear in different sites and at different times; collection timing, concentration and staining should fit the suspected target. A negative single stool examination can miss intermittent shedding, whereas delayed processing may destroy fragile forms. Viral antigen tests detect a protein target; nucleic-acid amplification detects genetic material and can be sensitive even when infectious virus is no longer present. Serology measures host response and can lag behind infection or remain positive later. Read the assay's target, specimen site, collection time and internal controls before interpreting a result. An inhibition flag makes a negative amplification result unreliable. Report the detected laboratory finding without inferring organism viability or the cause of symptoms from one test.

Worked example: A respiratory nucleic-acid assay remains positive after a patient's symptoms resolve. Its internal control passes, so target material was detected in that specimen. The result does not establish that viable virus remains or that the patient is still infectious. The technician reports the assay result with its required qualifiers; interpretation uses the collection site, dates and any additional testing specified for the case.

Watch the distinction: A positive viral nucleic-acid result does not always prove active replication. Genetic material may persist after symptoms, and the assay generally does not test whether intact infectious virus is present.

51. Antimicrobial susceptibility

An MIC is the lowest tested drug concentration that inhibits visible growth under the specified method. A disk-diffusion zone reflects growth inhibition around a drug disk. Neither number has a universal susceptible meaning: interpret it using the supplied organism, drug, method and category criteria. A smaller MIC for one drug cannot be compared casually with another drug's MIC because dosing, achievable exposure and breakpoints differ. Before assigning a category, verify isolate purity and identification, inoculum and incubation conditions, media, and quality-control organism results. Unexpected resistance patterns can signal a mixed culture, method problem or clinically important mechanism requiring confirmation. Report the measured result and category permitted by the validated method, and escalate unusual findings. Susceptibility is laboratory evidence; choosing a patient's treatment is outside the technician's role.

Worked example: A hypothetical isolate has an MIC of 2 mg/L for drug X. The supplied organism-drug rule defines susceptible as at most 1 mg/L and intermediate as 2–4 mg/L. Since 2 lies in that range, the category is intermediate. The technician first confirms that the isolate identification and method controls pass, then reports the category through the authorized workflow. The MIC alone does not select therapy.

Watch the distinction: Assuming an MIC of 2 mg/L is always susceptible treats breakpoints as universal. The interpretation depends on the specific organism, drug and validated method criteria supplied for that test.

52. Molecular and mass-spectrometric identification

Nucleic-acid amplification and mass spectrometry identify organisms through different signals. Amplification makes a target sequence detectable, but carryover product or specimen contamination can produce false positives; an internal control helps reveal inhibition that could make a negative result unreliable. A negative extraction or run control that amplifies signals a compromised run. Mass-spectrometric identification compares an isolate's protein spectrum with a reference database. Its answer depends on colony purity, sample preparation and whether close relatives are adequately represented in that database. Low-confidence or conflicting identifications need another validated method or referral. Review control results before patient calls, then compare identification with stain, growth and specimen source. Certain suspicious organisms or urgent molecular findings require prompt notification and containment through authorized channels, without attempting unsafe confirmatory manipulation.

Worked example: A patient's molecular target and the run's negative control both amplify. Because the control should contain no target, contamination is possible and the patient result is invalid. The technician holds reporting, investigates preparation and reagent sources, and repeats the test with acceptable controls. A second positive patient result in a valid run can then be interpreted under the stated algorithm; the first run cannot support an organism claim.

Watch the distinction: A strong patient amplification curve cannot rescue a run whose negative control amplified. Control failure shows the testing environment or reagents may have introduced target material into that run.

53. Patient and specimen identification

Reliable results begin with matching the person, order and tube at collection. Use the required independent patient identifiers and label the specimen at the patient, so the label records the origin of the blood rather than an assumption made later. Compare requested tests with tube additive and fill requirements. Collection order matters when an additive from one tube could contaminate another: potassium EDTA carryover, for example, can raise measured potassium and lower calcium through chelation. Vigorous handling, difficult collection or delayed processing can rupture cells and alter analytes. At receipt, assess identity, container, volume and visible condition before analysis; no plausible result pattern repairs uncertain identity. The related phlebotomy technician guide covers collection skills that support these checks. Document discrepancies and follow the rejection or recollection route.

Worked example: A chemistry tube's label names a different patient identifier from the electronic order. The technician stops accessioning or testing and checks the collection record through the authorized discrepancy process. Even if potassium, sodium and glucose look plausible, they cannot establish whose blood is present. The sample is held or rejected as required, and an appropriately identified recollection is requested; no identifier is guessed from the paperwork.

Watch the distinction: Matching an order number or recognizing a patient's usual results does not establish specimen identity. The tube itself must be traceable to the correctly identified patient at collection.

54. Errors across the testing chain

Errors can enter before testing, during measurement or after an instrument produces a valid result. A wrong tube or delayed separation is preanalytical; a calibration failure is analytical; a wrong interface map or transcription is postanalytical. Locate the first point where the recorded value diverges from the trustworthy source. Compare accession data, analyzer printout, interface message, report display and audit trail while preventing release of suspect results. If a wrong report already reached a recipient, the correction must preserve the original entry, identify the corrected value and document notification through the laboratory's authorized process. Also search for other patients affected by the same mapping or configuration fault. An audit trail makes the sequence reconstructable; silently overwriting a value destroys evidence needed for patient safety and quality review.

Worked example: An analyzer records potassium at 4.2 mmol/L, but the patient report displays 42 mmol/L. The accession and specimen identity match, and the interface log shows 4.2 entering the system. The divergence occurs after transmission, so the technician stops release and investigates the report mapping. If 42 was already issued, a documented corrected report and recipient notification are required; affected reports from the same interface are checked.

Watch the distinction: Repeating the patient's measurement will not fix a misplaced decimal introduced after analysis. Trace the value through the interface and report, then correct the postanalytical fault and affected records.

55. QC statistics

Quality-control statistics describe different aspects of performance. The mean is the average of repeated control measurements. Standard deviation summarizes spread around that mean; for a small sample used to estimate future variation, divide the sum of squared deviations by n − 1 before taking the square root. Coefficient of variation, SD ÷ mean × 100%, expresses imprecision relative to concentration. Bias compares a run or method mean with an assigned target, often as (mean − target) ÷ target × 100%. A tight cluster can be precise yet consistently high, so precision does not guarantee accuracy. Plot results over time because shifts suggest systematic change while scattered isolated points suggest random error. Check the control level and units: a CV at one concentration does not automatically describe performance at another.

Worked example: Hypothetical control values are 98, 100 and 102 U/L. Their mean is 300 ÷ 3 = 100 U/L. The sample SD is √[(4 + 0 + 4)/(3 − 1)] = 2 U/L, so CV = 2/100 × 100 = 2%. Against an assigned target of 95 U/L, percent bias is (100 − 95)/95 × 100 = +5.26%. The results are fairly tight but centered high.

Watch the distinction: A low CV does not prove a method is accurate. CV measures spread; a consistently displaced mean can produce a low CV and still show systematic bias.

56. Control charts and calibration

A control chart places results relative to an established mean and SD so changes become visible before patient values are released. Apply the rule actually specified for the run: one isolated outlier, two successive controls on the same side, a shift and a trend can call for different actions. When a rejection rule is met, hold affected patient results, investigate reagents, calibration, maintenance and specimen handling, then document corrective action and acceptable repeat controls. Calibration establishes the relation between instrument signal and concentration; calibration verification checks whether that relation remains acceptable at selected concentrations. Neither rescues a patient result outside the validated analytical measurement range. Such a result may require an approved dilution or alternative method, with the final reportable range and calculation checked. Do not adjust a control target merely to absorb a new bias.

Worked example: A hypothetical laboratory rule rejects a run if two successive controls exceed +2 SD on the same side. Results of +2.3 SD and +2.4 SD meet it. The technician holds patient reports from the affected interval, checks reagent and calibration history, corrects the identified cause and reruns controls. Only after the controls pass and affected specimens are addressed can authorized reporting resume.

Watch the distinction: Two high controls meeting a stated rejection rule are not made acceptable by a patient result that looks reasonable. The control pattern challenges the measurement system itself.

57. Laboratory calculations and equipment

Dimensional analysis keeps laboratory preparation and result calculations consistent. A 1:5 dilution means one part specimen in five parts final mixture, so its dilution factor is five. For a required final volume, divide by five to find specimen volume; the remainder is diluent. Multiplying the measured diluted result by five estimates the original concentration only when the method validates that dilution and the value remains reportable. Equipment settings can defeat correct arithmetic. Pipette calibration affects delivered volume; centrifugation depends on relative centrifugal force, which also depends on rotor radius, not speed alone. Microscope calibration affects measured dimensions, and monitored temperature preserves reagents and specimens within their validated conditions. Check units and equipment status before preparing a dilution or accepting a calculation. Record the actual volumes and any permitted rounding.

Worked example: A hypothetical method calls for 10 mL of a 1:5 dilution. Specimen volume is 10 ÷ 5 = 2 mL, so add 8 mL diluent. If the diluted sample measures 10 U/mL on a validated run, estimated original concentration is 10 × 5 = 50 U/mL. An out-of-calibration pipette makes the actual ratio uncertain, so that result cannot be accepted until the preparation is corrected.

Watch the distinction: Using 2 mL specimen plus 10 mL diluent does not make a 1:5 dilution; the 12 mL final volume makes it 1:6. Count total parts, including specimen.

58. Safe laboratory work

Standard precautions treat blood and other potentially infectious material as possible exposure sources. Choose gloves, eye or face protection and protective clothing for the likely splash or contact route, then remove contaminated items without spreading material. Sharps belong in an appropriate nearby container; recapping a used needle adds a puncture opportunity. After an exposure, stop the task, perform the institution's immediate first-aid steps and report promptly so the designated team can assess it and preserve records. Chemical hazards require reading the container label and safety-data sheet, using the stated ventilation and spill response, and segregating incompatible waste. Electrical or fire hazards call for isolating the source when safe and activating the facility response. The technician follows these routes and reports facts; exposure assessment and treatment decisions belong to authorized personnel.

Worked example: A used needle punctures a technician's finger during disposal. The technician stops work, performs the institution's immediate wound-care steps and reports the exposure through the designated channel without delay. The needle goes into the sharps container without recapping, and the event details are documented for the authorized exposure assessment. Continuing the run first would delay that assessment and risk another injury.

Watch the distinction: Recapping a contaminated needle to keep the bench tidy increases sharps risk. Place it directly in the approved container and use the prescribed exposure route if a puncture occurs.

59. Critical results and corrections

A critical result is one that meets the laboratory's stated urgent-notification criterion, which must be supplied rather than assumed. Before communication, verify specimen identity, relevant analyzer flags, quality control and any method-specific interference; prompt verification should not create avoidable delay. Notify the designated recipient through an authorized channel, give the patient identifier, test, value and units, and obtain a read-back when required. Record the time, recipient and confirmation. An unexpected result below a critical boundary may still need investigation or supervisory review under procedure. If an already released value proves wrong, issue a traceable corrected report and notify those who received the earlier result. The technician communicates laboratory findings and their limitations; decisions about diagnosis or treatment remain with the patient's clinical team.

Worked example: In a hypothetical case, the laboratory's urgent potassium boundary is at least 6.5 mmol/L. A correctly identified specimen yields 6.8 mmol/L, controls pass and the method's hemolysis check shows no interference. Since 6.8 meets the supplied boundary, the technician promptly contacts the designated clinician, obtains the required read-back and records the recipient and time. The report gives the verified value; it does not prescribe treatment.

Watch the distinction: Entering a critical value in the electronic record alone may not satisfy the stated notification process. Complete the required direct communication, read-back and documentation after prompt result verification.

60. Competence and quality systems

Quality systems connect daily technical work with documented evidence that the laboratory's methods remain reliable. Competency assessment checks whether a person can perform and interpret assigned tasks; proficiency testing compares an unknown sample with an external assessment process. A discrepancy calls for investigation of preparation, calibration, method limits, transcription and staff technique, including whether patient work was affected. Preserve original records and the audit trail so the cause can be reconstructed. An undocumented calibration change can shift results even when an instrument continues producing numbers. Stop work beyond your authorization and bring such findings to the supervisor or designated specialist for review. The American Society for Clinical Pathology provides information about its certification programs; laboratory procedures and authorization still govern what the technician may perform and release.

Worked example: A proficiency sample differs from the peer result, and the technician finds an undocumented calibration change made before the sample was run. The technician preserves the instrument, calibration and reporting records, notifies the supervisor and identifies patient results from the affected interval for review. The discrepancy is investigated before routine release resumes. Repeating only the proficiency sample would leave the possible patient-result impact unresolved.

Watch the distinction: A poor proficiency result is not repaired by quietly changing the recorded value or rerunning until it agrees. Preserve the original evidence and investigate method performance and affected patient work.